journal
MENU ▼
Read by QxMD icon Read
search

Chinese Clinical Oncology

journal
https://www.readbyqxmd.com/read/29307196/emilia-use-cunning-to-survive-cancer
#1
EDITORIAL
Joseph Gligorov, Sandrine Richard, Xavier Pivot
No abstract text is available yet for this article.
January 3, 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29307195/choice-of-chemotherapy-regimen-for-early-her2-positive-breast-cancer-in-elderly-patients
#2
EDITORIAL
Noam Pondé, Evandro de Azambuja
No abstract text is available yet for this article.
December 14, 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29307204/targeting-the-stroma-in-pancreatic-cancer
#3
Daniel H Ahn, Ramesh K Ramanathan
The tumor stroma in pancreatic adenocarcinoma is recognized as an integral component in tumorigenesis through its effects on cell signaling, immunosuppression and inhibitory effect on therapeutic agents. Promising preclinical activity has been observed with novel therapeutic agents that target the tumor microenvironment and represent one of many potential treatment strategies of interest in this disease. Herein, we will highlight and review therapeutic novel agents aimed at tumor stroma in pancreas cancer.
December 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29307203/interventional-endoscopy-in-the-diagnosis-and-management-of-pancreatic-adenocarcinoma
#4
Asim S Khokhar, Amna F Sher, Mark Schattner
Pancreatic cancer accounts for approximately 3% of all cancers in US, and is the fourth leading cause of mortality in both men and women. It is a silent killer due to lack of early symptoms and the majority of patients present at advanced stage at the time of initial diagnosis. Only 15-20% of patients are candidates for curative resection and even then, the 5-year survival rates range from 10-25%. Despite recent advances in the treatment of advanced pancreatic cancer, the prognosis remains grim with 5-year overall survival (OS) of approximately 10%...
December 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29307202/imaging-for-pancreatic-ductal-adenocarcinoma
#5
Natally Horvat, Davinia E Ryan, Maria D LaGratta, Pari M Shah, Richard Kinh Do
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers worldwide due to its aggressiveness and the challenge to early diagnosis. Complete surgical resection is the only curative option, but fewer than 20% of patients have potentially resectable disease at the time of the diagnosis. Radiologists can assess whether PDAC is resectable, borderline resectable, locally advanced or metastatic based on current imaging tests. This review will outline the role of imaging in both the diagnosis and staging of PDAC, with the goal of assisting the multidisciplinary team in tailoring the best treatment for patients...
December 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29307201/risk-factors-biomarker-and-imaging-techniques-used-for-pancreatic-cancer-screening
#6
Cyrus Thomas
Pancreatic cancer (PC) is one of the most lethal epithelial malignancies. There have been many attempts aimed at improving survival rates; however, the fatality of PC has been attributed to its few, nonspecific and diverse symptoms that delay diagnosis, rapid metastatic progression and overall treatment resistance. The aggressive nature of PC has stimulated interest in detecting smaller asymptomatic cancers or precursor lesions that are more likely to be curable. This review discusses potential risk factors including lifestyle and genetic variables that are believed to be the most important in contributing to the development of PC...
December 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29307200/the-diagnosis-and-management-of-cystic-lesions-of-the-pancreas
#7
Peter J Allen
Cystic lesions of the pancreas are radiographic findings that have a very broad histologic differential. This differential spans the spectrum from benign to cancerous, and includes non-neoplastic pseudocysts, benign neoplastic cysts, pre-malignant cysts, and cystic lesions with invasive carcinoma. This chapter will highlight the challenges with diagnosis and management of patients who present with cystic neoplasms of the pancreas.
December 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29307199/pathologic-classification-of-pancreatic-cancers-current-concepts-and-challenges
#8
Mohamed E Mostafa, Ipek Erbarut-Seven, Burcin Pehlivanoglu, Volkan Adsay
As the most common and most important cancer of the pancreas, with rapid mortality and now also as the third leading cause of cancer-related deaths in the United States, pancreatic ductal adenocarcinoma (PDAC) has become synonymous with "pancreas cancer". PDAC is also the prototype of the "pancreatobiliary-type" adenocarcinomas, along the biliary tract, ampullary and gallbladder cancers with the similar morphology and behavior. Recent molecular profiling studies have identified distinct subsets of PDAC, potentially with different behaviors and targetability...
December 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29307198/inherited-pancreatic-cancer
#9
Fei Chen, Nicholas J Roberts, Alison P Klein
Pancreatic cancers arise through a series of genetic events both inherited and acquired. Inherited genetic changes, both high penetrance and low penetrance, are an important component of pancreatic cancer risk, and may be used to characterize populations who will benefit from early detection. Furthermore, pancreatic cancer patients with inherited mutations may be particularly sensitive to certain targeted agents, providing an opportunity to personalized treatment. Family history of pancreatic cancer is one of the strongest risk factors for the disease, and is associated with an increased risk of caners at other sites, including but not limited to breast, ovarian and colorectal cancer...
December 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29307197/preface-for-special-edition-pancreas-cancer
#10
Eileen M O'Reilly, Lei Zheng
No abstract text is available yet for this article.
December 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29156891/investigating-the-role-of-tumor-infiltrating-lymphocytes-in-advanced-her2-positive-breast-cancer
#11
EDITORIAL
Stephen J Luen, Sherene Loi
No abstract text is available yet for this article.
November 14, 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29156890/why-the-results-of-adjuvant-pertuzumab-in-her2-positive-early-breast-cancer-has-been-received-as-a-mitigate-success
#12
EDITORIAL
Xavier Pivot, David G Cox, Joseph Gligorov
No abstract text is available yet for this article.
November 9, 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29156892/trastuzumab-emtansine-in-her2-positive-metastatic-breast-cancer-what-is-the-best-sequence
#13
EDITORIAL
Francesco Ricci, Christophe Le Tourneau
No abstract text is available yet for this article.
November 6, 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29156889/chemotherapy-induced-oral-mucositis-prevention-is-possible
#14
E Una Cidon
BACKGROUND: Oral mucositis (OM) is an inflammation of the oral mucosa which occurs in 20-40% of patients receiving conventional chemotherapy (CM). Many different substances have been used separately to treat or prevent OM but no standard procedure has been settled as definitive. We conducted a prospective study to examine whether rinses with a mixture of soluble prednisolone, nystatin and salt water applied before the expected OM appears, would reduce the incidence of grade 2-3 OM in subsequent cycles of CM...
November 3, 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29156888/chimeric-antigen-receptor-car-t-and-other-t-cell-strategies-for-pancreas-adenocarcinoma
#15
Anna M Varghese
Treatments in metastatic pancreas cancer remain based in cytotoxic chemotherapy, and novel treatment strategies are needed. Building on the emerging role of T cell therapy in hematologic malignancies and our understanding of the underlying biology of pancreas cancer, research is growing in the role of T cell therapy for patients with solid tumors in general and more specifically patients with pancreas cancer. This review will focus on describing the biology of T cell therapy and its current applications in pancreas cancer...
October 24, 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29156886/advocacy-and-pancreas-cancer-a-new-world
#16
Jane Mahoney Holt, Matthew R Alsante
No abstract text is available yet for this article.
October 20, 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29129096/eras-tubeless-michael-haddock-the-past-and-future-of-proton-beam
#17
Bella Poon, Helen Seliman
No abstract text is available yet for this article.
October 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29129095/trastuzumab-biosimilar-in-early-breast-cancer-setting-will-there-be-direct-patient-benefits
#18
Arlene Chan
No abstract text is available yet for this article.
October 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29129094/rational-combination-of-immunotherapy-for-triple-negative-breast-cancer-treatment
#19
Chia-Wei Li, Seung-Oe Lim, Jennifer L Hsu, Mien-Chie Hung
Recent evidence indicates that tumor infiltrating lymphocytes (TILs), including cytotoxic T cells, are present in the tumor microenvironment of triple-negative breast cancers (TNBC). Despite the presence of cytotoxic T cells, these tumors still develop, progress, and metastasize, suggesting evasion of immune response. One mechanism of immunosuppression is the presence of the T cell inhibitory molecule, programmed death protein 1 (PD-1), on infiltrating T cells and its cognate ligand programmed death ligand 1 (PD-L1) on tumor cells, myeloid dendritic cells (DCs), and macrophages, in the tumor microenvironment...
October 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29129093/xxxxx
#20
Tomas G Lyons, Geoffrey Y Ku
The poor prognosis for patients with esophagogastric cancers (EGC) requires the development of newer more effective therapies to further improve the treatment outcomes for this disease. Immunotherapy is a novel treatment strategy that is dramatically changing the treatment landscape for several types of cancers. Cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed death the programmed death (PD)-1/PD-ligand are essential immune checkpoint inhibitors that suppress T cell activation. Targeting of these immune checkpoints with monoclonal antibodies has shown clinical efficacy in several solid tumors which has led to their approval and use in routine clinical practice...
October 2017: Chinese Clinical Oncology
journal
journal
47887
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"